Figure 5.

Myeloid-specific Pfkfb3 deficiency attenuates LPS-induced inflammatory responses. (A) Representative images (left) and quantification (right) for immunohistochemical staining of the neutrophil marker Ly6G in lung sections of Pfkfb3^WT mice and Pfkfb3^ΔMϕ mice 6 h after LPS injection (n = 5). (B) Representative images (left) and quantification (right) for immunohistochemical staining of the macrophage marker Mac2 in lung sections of Pfkfb3^WT mice and Pfkfb3^ΔMϕ mice 6 h after LPS injection (n = 5). (C–E) qPCR analysis of the mRNA levels of Il1b (C), Il6 (D) and Nos2 (E) in the lung of Pfkfb3^WT mice and Pfkfb3^ΔMϕ mice 6 h after LPS injection (n = 6). (F,G) ELISA analysis of Il1b (F) and Il6 (G) in serum of Pfkfb3^WT mice and Pfkfb3^ΔMϕ mice 6 h after LPS injection (n = 4). (H) NO levels in serum of Pfkfb3^WT mice and Pfkfb3^ΔMϕ mice 6 h after LPS injection (n = 3–4). All data are represented as mean ± SEM, **P < 0.01 and ***P < 0.001 for Pfkfb3^WT vs. Pfkfb3^ΔMϕ (unpaired two-tailed Student's t test).